A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms COSMiC
- Sponsors Janssen Inc
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2018 Results (n=264) data cut off as of September 2017 evaluating patient related outcomes in real world when treated with abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC) population presented at the 2018 Genitourinary Cancers Symposium.
- 25 Oct 2017 Planned primary completion date changed from 15 Aug 2017 to 30 Oct 2018.